EUCTR2007-001214-16-IT进行中（未招募）不适用
A randomized, double-blind, placebo-controlled, parallel-group, multi-centre, Phase IIb, study to determine the effect of BXL628 in women with detrusor overactivity - BXL628 effect in OAB
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- BIOXELL SPA
- 入组人数
- 234
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •-Women aged 18-75 years
- •-Patients must have had symptoms of overactive bladder (OAB) for at least 6 months
- •-Patients must exhibit all of the following symptoms during the three-day diary collecting period prior to start of treatment: frequency at least 8 times per 24 h, urgency at least once per 24 h with or without one episode of urge incontinence in 24h.
- •-Urodynamically confirmed detrusor overactivity. A urodynamic evaluation dated within 6 months before the enrolment can be considered valid
- •-Patients on anticholinergic /antispasmodic drugs for the treatment of OAB must discontinue this treatment at visit 1 (at least 14 days prior to visit 2).
- •-Women of childbearing potential should use two well established contraceptive methods (e.g. contraceptive pill and condom, IUD and condom) or abstain from sexual intercourse
- •-Patients must be capable of independent toileting
- •-Ability to fully understand all study procedures and to provide written informed consent to study participation
- •-Ability to comply with dosing and study visits scheduled for the duration of 1 month
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Patients with predominant stress incontinence
- •-Patients with well established neurological disorder (e.g. Multiple Sclerosis, Parkinson?s disease, Alzheimer disease)
- •-Patients with pelvic organ prolapse staged III or IV (ICS classification)
- •-Patients who have undergone urogenital surgery such as hysterectomy less than 6 months prior to visit 1
- •-Painful bladder syndrome
- •-Patients with clinically significant bladder outlet obstruction and/or patients with a post void residual volume (PVR) ultrasound result, greater than 100 ml
- •-Patients with total daily volume greater than 2.8 l of voided urine
- •-History of acute urinary retention or history of repeated catheterizations due to acute urinary retention within the 3 months prior to visit 1
- •-Patients who intend to start a bladder training programme while in the study
- •-Patients with an indwelling catheter and patients practising intermittent self-catheterisation
- •-Patients who have undergone bladder biopsy or any other minor pelvic surgical intervention less than 30 days prior to visit 1
- •-Bladder cancer
- •-Patients with acute or recurrent urinary tract infection (UTI) and/or unexplained haematuria
- •-Stone in the bladder or urethra and upper tract stone disease causing symptoms
- •-Evidence of renal insufficiency (creatinine > 1.5 x upper limit of normal)
- •-Evidence of hepatic disease (total bilirubin > 1.5 x upper limit of normal, or AST or ALT or alkaline phosphatase > 2 x upper limit of normal)
- •-Patients with other clinically significant systemic diseases that may interfere with participation in this study
- •-Patients who are abusers of alcohol and/or other drugs
- •-History of disturbed calcium, phosphorus or magnesium metabolism
- •-Patients with allergy, hypersensitivity or other medical contraindications to Vitamin D
- •-Patients taking any of the following at any time during the study: Anticholinergic /antispasmodic drugs for the treatment of OAB; Calcitriol and other vitamin D analogs; Cholestiramine and other bile acid-binding resins; Cardiac glycosides; Drugs containing magnesium; Anticonvulsants; Estrogen treatment (unless started more than 2 months before randomization; estrogen containing oral contraceptives are allowed)
- •-Patients who have received any investigational drug during the preceding 90 days or 5 times the plasma half-life (if known), whichever is longer, or who have previously participated in this trial
- •-Patients unable and/or unlikely to comprehend and follow the study procedures and instructions
研究者
相似试验
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II. - ACCELAPeripheral Arterial Disease (PAD) Fontaine stage II (intermittent claudication)MedDRA version: 8.1Level: LLTClassification code 10022562Term: Intermittent claudicationEUCTR2006-004275-35-FRsanofi-aventis recherche & développement550
进行中（未招募）
不适用
A study to determine the appropriate dose(s) of Dupilumab (REGN668)in adult patients with moderate to severe atopic dermatitis (eczema)Atopic dermatitsMedDRA version: 16.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2012-003651-11-PLRegeneron Pharmaceuticals, Inc.240
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II. - ACCELAPeripheral Arterial Disease (PAD) Fontaine stage II (intermittent claudication)MedDRA version: 8.1Level: LLTClassification code 10022562Term: Intermittent claudicationEUCTR2006-004275-35-ATsanofi-aventis recherche & développement550
进行中（未招募）
1 期
Efficacy and safety of dexketoprofen trometamol and tramadol hydrochloride combination on moderate to severe acute pain in patients with acute low back paiow back painMedDRA version: 21.0Level: LLTClassification code 10024891Term: Low back painSystem Organ Class: 100000004859EUCTR2019-003656-37-ESMenarini International Operations Luxembourg SA538
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy.Rheumatoid ArthritisEUCTR2004-005210-37-DEF. Hoffmann La-Roche AG1,200